IRIS Accounts Production v25.1.3.33 09125819 Board of Directors 1.3.24 28.2.25 28.2.25 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh091258192024-02-29091258192025-02-28091258192024-03-012025-02-28091258192023-02-28091258192023-03-012024-02-29091258192024-02-2909125819ns15:EnglandWales2024-03-012025-02-2809125819ns14:PoundSterling2024-03-012025-02-2809125819ns10:Director12024-03-012025-02-2809125819ns10:PrivateLimitedCompanyLtd2024-03-012025-02-2809125819ns10:SmallEntities2024-03-012025-02-2809125819ns10:AuditExempt-NoAccountantsReport2024-03-012025-02-2809125819ns10:SmallCompaniesRegimeForDirectorsReport2024-03-012025-02-2809125819ns10:SmallCompaniesRegimeForAccounts2024-03-012025-02-2809125819ns10:FullAccounts2024-03-012025-02-2809125819ns10:OrdinaryShareClass12024-03-012025-02-2809125819ns10:Director22024-03-012025-02-2809125819ns10:CompanySecretary12024-03-012025-02-2809125819ns10:RegisteredOffice2024-03-012025-02-2809125819ns5:CurrentFinancialInstruments2025-02-2809125819ns5:CurrentFinancialInstruments2024-02-2909125819ns5:Non-currentFinancialInstruments2025-02-2809125819ns5:Non-currentFinancialInstruments2024-02-2909125819ns5:ShareCapital2025-02-2809125819ns5:ShareCapital2024-02-2909125819ns5:RetainedEarningsAccumulatedLosses2025-02-2809125819ns5:RetainedEarningsAccumulatedLosses2024-02-2909125819ns5:FurnitureFittings2024-03-012025-02-2809125819ns5:MotorVehicles2024-03-012025-02-2809125819ns5:ComputerEquipment2024-03-012025-02-2809125819ns5:FurnitureFittings2024-02-2909125819ns5:MotorVehicles2024-02-2909125819ns5:ComputerEquipment2024-02-2909125819ns5:FurnitureFittings2025-02-2809125819ns5:MotorVehicles2025-02-2809125819ns5:ComputerEquipment2025-02-2809125819ns5:FurnitureFittings2024-02-2909125819ns5:MotorVehicles2024-02-2909125819ns5:ComputerEquipment2024-02-2909125819ns5:WithinOneYearns5:CurrentFinancialInstruments2025-02-2809125819ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-2909125819ns10:OrdinaryShareClass12025-02-2809125819ns5:RetainedEarningsAccumulatedLosses2024-02-2909125819ns5:RetainedEarningsAccumulatedLosses2024-03-012025-02-28091258191ns10:Director12024-02-29091258191ns10:Director12023-02-28091258191ns10:Director12024-03-012025-02-28091258191ns10:Director12023-03-012024-02-29091258191ns10:Director12025-02-28091258191ns10:Director12024-02-2909125819ns10:Director222024-02-2909125819ns10:Director222023-02-2809125819ns10:Director222024-03-012025-02-2809125819ns10:Director222023-03-012024-02-2909125819ns10:Director222025-02-2809125819ns10:Director222024-02-29
REGISTERED NUMBER: 09125819 (England and Wales)














KG PHARMACONSULTING LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 28 FEBRUARY 2025






KG PHARMACONSULTING LTD (REGISTERED NUMBER: 09125819)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


KG PHARMACONSULTING LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 28 FEBRUARY 2025







DIRECTORS: K A Gunawardena
B A Gunawardena





SECRETARY: B A Gunawardena





REGISTERED OFFICE: Cherry Trees
Allendale Avenue
Worthing
West Sussex
BN14 0AH





REGISTERED NUMBER: 09125819 (England and Wales)





ACCOUNTANTS: Morris Crocker
Chartered Accountants
Station House
North Street
Havant
Hampshire
PO9 1QU

KG PHARMACONSULTING LTD (REGISTERED NUMBER: 09125819)

STATEMENT OF FINANCIAL POSITION
28 FEBRUARY 2025

2025 2024
Notes £    £    £   
FIXED ASSETS
Property, plant and equipment 4 50,800 67,398

CURRENT ASSETS
Debtors 5 32,031 23,934
Cash at bank 11,571 34,727
43,602 58,661
CREDITORS
Amounts falling due within one year 6 9,787 1,610
NET CURRENT ASSETS 33,815 57,051
TOTAL ASSETS LESS CURRENT
LIABILITIES

84,615

124,449

CREDITORS
Amounts falling due after more than one
year

7

69,044

76,579
NET ASSETS 15,571 47,870

CAPITAL AND RESERVES
Called up share capital 8 10 10
Retained earnings 9 15,561 47,860
SHAREHOLDERS' FUNDS 15,571 47,870

KG PHARMACONSULTING LTD (REGISTERED NUMBER: 09125819)

STATEMENT OF FINANCIAL POSITION - continued
28 FEBRUARY 2025


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 May 2025 and were signed on its behalf by:





K A Gunawardena - Director


KG PHARMACONSULTING LTD (REGISTERED NUMBER: 09125819)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1. STATUTORY INFORMATION

KG PharmaConsulting Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents net invoiced sales of goods and services, excluding value added tax.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 20% on reducing balance
Motor vehicles - 25% on reducing balance
Computer equipment - 50% on cost

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, loans from banks and other third parties and loans to related parties and investments in non-puttable ordinary shares.

Trade and other debtors
Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment

Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, deposits with banks and other short-term highly liquid investments and bank overdrafts. In the balance sheet, bank overdrafts are shown within borrowings or current liabilities.

Trade and other creditors
Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.


KG PHARMACONSULTING LTD (REGISTERED NUMBER: 09125819)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

4. PROPERTY, PLANT AND EQUIPMENT
Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
COST
At 1 March 2024 125 89,083 14,069 103,277
Additions - - 758 758
At 28 February 2025 125 89,083 14,827 104,035
DEPRECIATION
At 1 March 2024 61 22,271 13,547 35,879
Charge for year 13 16,703 640 17,356
At 28 February 2025 74 38,974 14,187 53,235
NET BOOK VALUE
At 28 February 2025 51 50,109 640 50,800
At 29 February 2024 64 66,812 522 67,398

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Directors' current accounts 26,459 17,626
Corporation tax recoverable 5,515 6,242
VAT 57 66
32,031 23,934

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Hire purchase contracts 8,013 -
Other creditors 175 10
Accrued expenses 1,599 1,600
9,787 1,610

KG PHARMACONSULTING LTD (REGISTERED NUMBER: 09125819)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2025 2024
£    £   
Hire purchase contracts 69,044 76,579

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
10 Ordinary £1 10 10

9. RESERVES
Retained
earnings
£   

At 1 March 2024 47,860
Deficit for the year (32,299 )
At 28 February 2025 15,561

10. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 28 February 2025 and 29 February 2024:

2025 2024
£    £   
K A Gunawardena
Balance outstanding at start of year 8,820 -
Amounts advanced 13,229 8,820
Amounts repaid (8,820 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 13,229 8,820

B A Gunawardena
Balance outstanding at start of year 8,805 -
Amounts advanced 13,229 8,805
Amounts repaid (8,805 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 13,229 8,805

11. ULTIMATE CONTROLLING PARTY

The company is under the control of Mr K Gunawardena and Mrs B Gunawardena and each own 50% of the issued share capital